Carl Zeiss: Recovery Has Started

Wolf Report Investing Group Leader Follow Summary Carl Zeiss Meditec remains a 'Strong Buy' despite prolonged challenges, with a revised price target of €65/share (ADR: $75.42). Core revenue remains resilient, but earnings are pressured by suboptimal product mix, China exposure, and negative operating leverage. Management is executing cost-cutting, product launches, and manufacturing shifts outside China, supporting a recovery thesis and downside protection. CZMWY offers low yield but high quality, a debt-free balance sheet, and double-digit upside potential on multiple expansion and earnings normalization. Looking for more investing ideas like this one? Get them exclusively at Wolf of Value. Learn More » Victor Golmer/iStock Editorial via Getty Images It's time to update my thesis for Carl Zeiss Meditec AG ( CZMWY ). This has been a company that I have unfortunately researched for a long period of time (unfortunate, because of the relatively deep negative RoR that the company has for This article was written by Wolf Report 35.41K Followers Follow Wolf Report is a senior analyst and private portfolio manager with over 10 years of generating value ideas in European and North American markets, and the owner of Wolf of Value, a service focusing on international dividend-paying value investments.He further covers the markets of Scandinavia, Germany, France, UK, Italy, Spain, Portugal and Eastern Europe in search of reasonably valued stock ideas. Analyst’s Disclosure: I/we have a beneficial long position in the shares of CZMWY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice. It may be structured as such, but it is not financial advice. Investors are required and expected to do their own due diligence and research prior to any investment. Short-term trading, options trading/investment and futures trading are potentially extremely risky investment styles. They generally are not appropriate for someone with limited capital, limited investment experience, or a lack of understanding for the necessary risk tolerance involved. I own the European/Scandinavian tickers (not the ADRs) of all European/Scandinavian companies listed in my articles. I own the Canadian tickers of all Canadian stocks I write about. Please note that investing in European/Non-US stocks comes with withholding tax risks specific to the company's domicile as well as your personal situation. Investors should always consult a tax professional as to the overall impact of dividend withholding taxes and ways to mitigate these. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.